Description
Bevacizumab Cizumab 400mg Injection, containing Bevacizumab, is prescribed alongside conventional chemotherapy to enhance treatment outcomes for metastatic breast, kidney, lung, colon, and rectum cancers. As a humanized monoclonal antibody, it targets vascular endothelial growth factor A, inhibiting angiogenesis crucial for cancer growth and spread. Indicated for adult patients, it is utilized in various combinations for different cancer types, including metastatic kidney cancer, non-small cell lung cancer, ovarian, fallopian tube, primary peritoneal cancer, and cervical cancer. Not recommended for patients allergic to Bevacizumab, those recently undergoing major surgery, or pregnant or breastfeeding women. Common side effects include constipation, appetite loss, fever, eye problems, and changes in speech or taste.
